Panitumumab

• UNSPSC Description:

  Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer[1][2][4].

• Target Antigen:

  EGFR

• Type:

  Inhibitory Antibodies

• Related Pathways:

  JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/panitumumab.html

• Purity:

  98.80

• Solubility:

  H2O

• Smiles:

  [Panitumumab]

• References & Citations:

  [1]Yu Jo Chua, et al. Panitumumab. Drugs Today (Barc). 2006 Nov;42(11):711-9.|[2]Stefan Stremitzer, et al. Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf. 2014 Jun;13(6):843-51.|[3]Daniel J. Freeman, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther (2009) 8 (6): 1536–1546.|[4]Efstathia Giannopoulou, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29(12):5077-82.|[5]Giannopoulou E, et al. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009 Dec;29(12):5077-82. PMID: 20044619.. . .

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Launched

• CAS Number:

  339177-26-3